Successful treatment of severe relapsing leukoencephalopathy form of Myelin oligodendrocyte glycoprotein associated disease (MOGAD)
International Journal of Therapeutic Innovation · 28.06.2026 · 4 (03) · 29-31
DOI: 10.55522/ijti.v4i3.0145 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Therapeutic Innovation, online erschienen am 28.06.2026. Verfasst von Reshma Sultana Shaik.
Abstract (Originalsprache)
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) was identified as a distinct entity from that of Neuromyelitis Optica (NMO) in 2007. MOGAD presents as either a monophasic or multiphasic demyelinating syndrome in adults and children. We present a case of Leukoencephalopathy-like illness in a young boy who presented to our tertiary care centre with a stormy, refractory course, which improved significantly after the introduction of Tocilizumab as the immunotherapy.
Zitieren
APA
Shaik, R. S. (2026). Successful treatment of severe relapsing leukoencephalopathy form of Myelin oligodendrocyte glycoprotein associated disease (MOGAD). International Journal of Therapeutic Innovation, 4(03), 29-31. https://doi.org/10.55522/ijti.v4i3.0145
Vancouver
Shaik RS. Successful treatment of severe relapsing leukoencephalopathy form of Myelin oligodendrocyte glycoprotein associated disease (MOGAD). International Journal of Therapeutic Innovation. 2026;4(03):29-31. doi:10.55522/ijti.v4i3.0145
BibTeX
@article{Shaik2026,
author = {Shaik, Reshma Sultana},
title = {Successful treatment of severe relapsing leukoencephalopathy form of Myelin oligodendrocyte glycoprotein associated disease (MOGAD)},
journal = {International Journal of Therapeutic Innovation},
year = {2026},
volume = {4},
number = {03},
pages = {29--31},
doi = {10.55522/ijti.v4i3.0145}
}
EUVIMED